s-1,2-dichlorovinyl-n-acetylcysteine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

S-1,2-dichlorovinyl-N-acetylcysteine: urinary metabolite of trichloroethylene in mice [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	6437866
SCHEMBL ID	20817477
MeSH ID	M0142290

Synonyms (16)

Synonym
s-1,2-dichlorovinyl-n-acetylcysteine
(2r)-2-acetamido-3-[(z)-1,2-dichloroethenyl]sulfanylpropanoic acid
s-dichlorovinyl-n-acetylcysteine
l-cysteine, n-acetyl-s-(1,2-dichloroethenyl)-
n-acetyl-s-(1,2-dichloroethenyl)-l-cysteine
2148-31-4
ccris 1304
J-014095
SCHEMBL20817477
126924-18-3
(2r)-2-acetamido-3-((z)-1,2-dichloroethenyl)sulfanylpropanoic acid
unii-d2jsz28hp5
d2jsz28hp5 ,
n-acetyl-s-(1,2-dichlorovinyl)-l-cysteine, (z)-
DTXSID701030744
(2r)-3-{[(1z)-1,2-dichloroethenyl]sulfanyl}-2-acetamidopropanoic acid

Research Excerpts

Toxicity

Excerpt	Reference	Relevance
" Safety was assessed by adverse events (AEs), treatment-related adverse events (TRAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs)."	( Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers. Cao, S; Han, B; Ling, X; Wang, H; Xu, J; Zhang, B; Zhang, X; Zhong, H; Zhong, R, 2022)	0.72
" DCVAC/OvCa showed a good safety profile with treatment-emergent adverse events related to DCVAC/OvCa in 2 of 34 patients (5."	( Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. Bartos, P; Bartunkova, J; Chovanec, J; Cibula, D; Fucikova, J; Hraska, M; Hrnciarova, T; Kieszko, D; Klat, J; Knapp, P; Korolkiewicz, RP; Mallmann, P; Melichar, B; Minar, L; Novotny, Z; Pluta, M; Rob, L; Spacek, J; Spisek, R; Valha, P, 2022)	0.72

Compound-Compound Interactions

Excerpt	Reference	Relevance
"Our prospective, open-label, single-arm phase II study investigated the safety and efficacy of DCVAC/LuCa (dendritic cell vaccines for lung cancer) combined with standard carboplatin/pemetrexed in advanced non-squamous (nsq) non-small-cell lung cancer (NSCLC)."	( Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers. Cao, S; Han, B; Ling, X; Wang, H; Xu, J; Zhang, B; Zhang, X; Zhong, H; Zhong, R, 2022)	0.72

Dosage Studied

Excerpt	Relevance	Reference
"N-Acetyl-S-(1,2-dichlorovinyl)-L-cysteine (NA-DCVC) has been detected in the urine of humans exposed to trichloroethylene and its related sulfoxide, N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine sulfoxide (NA-DCVCS), has been detected as hemoglobin adducts in blood of rats dosed with S-(1,2-dichlorovinyl)-L-cysteine (DCVC) or S-(1,2-dichlorovinyl)-L-cysteine sulfoxide (DCVCS)."	( Characterization of the chemical reactivity and nephrotoxicity of N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine sulfoxide, a potential reactive metabolite of trichloroethylene. Elfarra, AA; Irving, RM; Pinkerton, ME, 2013)	0.39

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (23.53)	18.7374
1990's	5 (29.41)	18.2507
2000's	2 (11.76)	29.6817
2010's	4 (23.53)	24.3611
2020's	2 (11.76)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.56 (24.57)
Research Supply Index	3.14 (2.92)
Research Growth Index	4.69 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.56)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	2 (10.00%)	5.53%
Reviews	1 (5.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	17 (85.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
p-aminohippuric acid p-Aminohippuric Acid: The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity.. p-aminohippurate : A hippurate that is the conjugate base of p-aminohippuric acid, arising from deprotonation of the carboxy group.. p-aminohippuric acid : An N-acylglycine that is the 4-amino derivative of hippuric acid; used as a diagnostic agent in the measurement of renal plasma flow.	1.98	1	0	N-acylglycine	Daphnia magna metabolite
probenecid Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.	2.38	2	0	benzoic acids; sulfonamide	uricosuric drug
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	2.43	2	0	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
trichloroethylene Trichloroethylene: A highly volatile inhalation anesthetic used mainly in short surgical procedures where light anesthesia with good analgesia is required. It is also used as an industrial solvent. Prolonged exposure to high concentrations of the vapor can lead to cardiotoxicity and neurological impairment.. triol : A chemical compound containing three hydroxy groups.	9.61	8	0	chloroethenes	inhalation anaesthetic; mouse metabolite
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	13.16	17	2	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
mercuric chloride Mercuric Chloride: Mercury chloride (HgCl2). A highly toxic compound that volatizes slightly at ordinary temperature and appreciably at 100 degrees C. It is corrosive to mucous membranes and used as a topical antiseptic and disinfectant.. mercury dichloride : A mercury coordination entity made up of linear triatomic molecules in which a mercury atom is bonded to two chlorines. Water-soluble, it is highly toxic. Once used in a wide variety of applications, including preserving wood and anatomical specimens, embalming and disinfecting, as an intensifier in photography, as a mordant for rabbit and beaver furs, and freeing gold from lead, its use has markedly declined as less toxic alternatives have been developed.	1.98	1	0	mercury coordination entity	sensitiser
alkenes [no description available]	1.97	1	0
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	4.72	1	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
homocysteine Homocysteine: A thiol-containing amino acid formed by a demethylation of METHIONINE.. homocysteine : A sulfur-containing amino acid consisting of a glycine core with a 2-mercaptoethyl side-chain.. L-homocysteine : A homocysteine that has L configuration.	2.38	2	0	amino acid zwitterion; homocysteine; serine family amino acid	fundamental metabolite; mouse metabolite
s-trichlorovinyl-n-acetylcysteine [no description available]	1.97	1	0	N-acyl-L-amino acid
carboplatin [no description available]	5.68	2	2
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	4.35	6	0	cysteinium	fundamental metabolite
s-(1,2-dichlorovinyl)cysteine S-(1,2-dichlorovinyl)cysteine: RN given refers to (L-Cys)-isomer; structure given in first source. S-(cis-1,2-dichlorovinyl)-L-cysteine : An S-(1,2-dichlorovinyl)-L-cysteine in which the dichlorovinyl group has cis- (Z-) geometry.	4.35	6	0	S-(1,2-dichlorovinyl)-L-cysteine
s-(1,2-dichlorovinyl)glutathione [no description available]	2.42	2	0	peptide
s-(1,2-dichlorovinyl)homocysteine S-(1,2-dichlorovinyl)homocysteine: RN given refers to (E)-isomer	2.38	2	0
calpain Calpain: Cysteine proteinase found in many tissues. Hydrolyzes a variety of endogenous proteins including NEUROPEPTIDES; CYTOSKELETAL PROTEINS; proteins from SMOOTH MUSCLE; CARDIAC MUSCLE; liver; platelets; and erythrocytes. Two subclasses having high and low calcium sensitivity are known. Removes Z-discs and M-lines from myofibrils. Activates phosphorylase kinase and cyclic nucleotide-independent protein kinase. This enzyme was formerly listed as EC 3.4.22.4.	2.03	1	0
n-acetyl-s-pentachloro-1,3-butadienylcysteine N-acetyl-S-pentachloro-1,3-butadienylcysteine: RN given refers to (L)-isomer; structure given in first source	1.97	1	0
calpastatin calpastatin: large mol wt, heat-stable calpain inhibitor; not based on sequestering Ca++ from medium, but binding to calpain does require Ca++. calpastatin peptide Ac 184-210 : A 27-membered polypeptide comprising the sequence Ac-Asp-Pro-Met-Ser-Ser-Thr-Tyr-Ile-Glu-Glu-Leu-Gly-Lys-Arg-Glu-Val-Thr-Ile-Pro-Pro-Lys-Tyr-Arg-Glu-Leu-Leu-Ala-NH2. An acetylated synthetic peptide from human calpastatin that strongly inhibits both calpains I and II but not papain (a cysteine protease) or trypsin (a serine protease).	2.03	1	0	polypeptide	EC 3.4.22.52 (calpain-1) inhibitor; EC 3.4.22.53 (calpain-2) inhibitor
s-(1,2-dichlorovinyl)-l-cysteine sulfoxide S-(1,2-dichlorovinyl)-L-cysteine sulfoxide: structure in first source	3.17	1	0
pemetrexed pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).	3.8	1	1	N-acyl-L-glutamic acid; pyrrolopyrimidine	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; EC 2.1.1.45 (thymidylate synthase) inhibitor; EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor

Condition	Relationship Strength	Studies	Trials
Carcinoma, Non-Small Cell Lung [description not available]	3.8	1	1
Cancer of Lung [description not available]	3.8	1	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	3.8	1	1
Lung Neoplasms Tumors or cancer of the LUNG.	3.8	1	1
Epithelial Ovarian Cancer [description not available]	4.72	1	1
Carcinoma, Ovarian Epithelial A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.	4.72	1	1
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	2.08	1	0
Acute Kidney Failure [description not available]	2.43	2	0
Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.	2.43	2	0
Alloxan Diabetes [description not available]	2.03	1	0
Cancer of Kidney [description not available]	1.96	1	0
Kidney Neoplasms Tumors or cancers of the KIDNEY.	1.96	1	0

chemdatabank.com